Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
WithdrawnPhase 2NCT05125978
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the efficacy and safety of Canadá association in the treatment of chronic pain
Study details
- Official title
- National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
- Conditions
- Interventions
- Drug: Canadá
- Other: Canadá placebo
- Drug: Dipyrone
- Other: Dipyrone placebo
- Drug: Tramadol hydrochloride
- Other: Tramadol hydrochloride placebo
- Sponsor
- EMS
- Start date
- 2026-09
- Primary completion
- 2028-07
- Sex
- All
- Age range
- from 15 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the consent form; * Chronic pain during at least 3 months. Exclusion Criteria: * Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of participants; * History of alcohol abuse or illicit drug use; * Participation in a clinical trial in the year prior to this study; * Pregnancy or risk of pregnacy and lactating participants; * Known hypersensitivity to any of the formula compounds.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05125978